These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1565 related items for PubMed ID: 28270207

  • 21. Bedaquiline and delamanid in the treatment of multidrug-resistant tuberculosis: Promising but challenging.
    Li Y, Sun F, Zhang W.
    Drug Dev Res; 2019 Feb; 80(1):98-105. PubMed ID: 30548290
    [Abstract] [Full Text] [Related]

  • 22. Culture Conversion in Patients Treated with Bedaquiline and/or Delamanid. A Prospective Multicountry Study.
    Franke MF, Khan P, Hewison C, Khan U, Huerga H, Seung KJ, Rich ML, Zarli K, Samieva N, Oyewusi L, Nair P, Mudassar M, Melikyan N, Lenggogeni P, Lecca L, Kumsa A, Khan M, Islam S, Hussein K, Docteur W, Chumburidze N, Berikova E, Atshemyan H, Atwood S, Alam M, Ahmed S, Bastard M, Mitnick CD.
    Am J Respir Crit Care Med; 2021 Jan 01; 203(1):111-119. PubMed ID: 32706644
    [Abstract] [Full Text] [Related]

  • 23. Clinical Outcomes Among Patients With Drug-resistant Tuberculosis Receiving Bedaquiline- or Delamanid-Containing Regimens.
    Kempker RR, Mikiashvili L, Zhao Y, Benkeser D, Barbakadze K, Bablishvili N, Avaliani Z, Peloquin CA, Blumberg HM, Kipiani M.
    Clin Infect Dis; 2020 Dec 03; 71(9):2336-2344. PubMed ID: 31712809
    [Abstract] [Full Text] [Related]

  • 24. Impact of adverse drug reactions on the incremental cost-effectiveness of bedaquiline for drug-resistant tuberculosis.
    Schnippel K, Firnhaber C, Page-Shipp L, Sinanovic E.
    Int J Tuberc Lung Dis; 2018 Aug 01; 22(8):918-925. PubMed ID: 29991402
    [Abstract] [Full Text] [Related]

  • 25. Delamanid when other anti-tuberculosis-treatment regimens failed due to resistance or tolerability.
    Kwon YS, Jeong BH, Koh WJ.
    Expert Opin Pharmacother; 2015 Feb 01; 16(2):253-61. PubMed ID: 25327169
    [Abstract] [Full Text] [Related]

  • 26. Bedaquiline and Delamanid Combination Treatment of 5 Patients with Pulmonary Extensively Drug-Resistant Tuberculosis.
    Maryandyshev A, Pontali E, Tiberi S, Akkerman O, Ganatra S, Sadutshang TD, Alffenaar JW, Amale R, Mullerpattan J, Topgyal S, Udwadia ZF, Centis R, D'Ambrosio L, Sotgiu G, Migliori GB.
    Emerg Infect Dis; 2017 Oct 01; 23(10):1718-21. PubMed ID: 28758888
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Combined Use of Delamanid and Bedaquiline to Treat Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis: A Systematic Review.
    Migliori GB, Pontali E, Sotgiu G, Centis R, D'Ambrosio L, Tiberi S, Tadolini M, Esposito S.
    Int J Mol Sci; 2017 Feb 07; 18(2):. PubMed ID: 28178199
    [Abstract] [Full Text] [Related]

  • 31. Delamanid: From discovery to its use for pulmonary multidrug-resistant tuberculosis (MDR-TB).
    Liu Y, Matsumoto M, Ishida H, Ohguro K, Yoshitake M, Gupta R, Geiter L, Hafkin J.
    Tuberculosis (Edinb); 2018 Jul 07; 111():20-30. PubMed ID: 30029909
    [Abstract] [Full Text] [Related]

  • 32. Outcome of treatment of MDR-TB or drug-resistant patients treated with bedaquiline and delamanid: Results from a large global cohort.
    Koirala S, Borisov S, Danila E, Mariandyshev A, Shrestha B, Lukhele N, Dalcolmo M, Shakya SR, Miliauskas S, Kuksa L, Manga S, Aleksa A, Denholm JT, Khadka HB, Skrahina A, Diktanas S, Ferrarese M, Bruchfeld J, Koleva A, Piubello A, Koirala GS, Udwadia ZF, Palmero DJ, Munoz-Torrico M, Gc R, Gualano G, Grecu VI, Motta I, Papavasileiou A, Li Y, Hoefsloot W, Kunst H, Mazza-Stalder J, Payen MC, Akkerman OW, Bernal E, Manfrin V, Matteelli A, Mustafa Hamdan H, Nieto Marcos M, Cadiñanos Loidi J, Cebrian Gallardo JJ, Duarte R, Escobar Salinas N, Gomez Rosso R, Laniado-Laborín R, Martínez Robles E, Quirós Fernandez S, Rendon A, Solovic I, Tadolini M, Viggiani P, Belilovski E, Boeree MJ, Cai Q, Davidavičienė E, Forsman LD, De Los Rios J, Drakšienė J, Duga A, Elamin SE, Filippov A, Garcia A, Gaudiesiute I, Gavazova B, Gayoso R, Gruslys V, Jonsson J, Khimova E, Madonsela G, Magis-Escurra C, Marchese V, Matei M, Moschos C, Nakčerienė B, Nicod L, Palmieri F, Pontarelli A, Šmite A, Souleymane MB, Vescovo M, Zablockis R, Zhurkin D, Alffenaar JW, Caminero JA, Codecasa LR, García-García JM, Esposito S, Saderi L, Spanevello A, Visca D, Tiberi S, Pontali E, Centis R, D'Ambrosio L, van den Boom M, Sotgiu G, Migliori GB.
    Pulmonology; 2021 Jul 07; 27(5):403-412. PubMed ID: 33753021
    [Abstract] [Full Text] [Related]

  • 33. Access to new medications for the treatment of drug-resistant tuberculosis: patient, provider and community perspectives.
    Lessem E, Cox H, Daniels C, Furin J, McKenna L, Mitnick CD, Mosidi T, Reed C, Seaworth B, Stillo J, Tisile P, von Delft D.
    Int J Infect Dis; 2015 Mar 07; 32():56-60. PubMed ID: 25809757
    [Abstract] [Full Text] [Related]

  • 34. Multi and extensively drug-resistant pulmonary tuberculosis: advances in diagnosis and management.
    Pontali E, Visca D, Centis R, D'Ambrosio L, Spanevello A, Migliori GB.
    Curr Opin Pulm Med; 2018 May 07; 24(3):244-252. PubMed ID: 29470252
    [Abstract] [Full Text] [Related]

  • 35. Use of bedaquiline and delamanid in diabetes patients: clinical and pharmacological considerations.
    Hu M, Zheng C, Gao F.
    Drug Des Devel Ther; 2016 May 07; 10():3983-3994. PubMed ID: 27994440
    [Abstract] [Full Text] [Related]

  • 36. Recent controversies about MDR and XDR-TB: Global implementation of the WHO shorter MDR-TB regimen and bedaquiline for all with MDR-TB?
    Dheda K, Cox H, Esmail A, Wasserman S, Chang KC, Lange C.
    Respirology; 2018 Jan 07; 23(1):36-45. PubMed ID: 28850767
    [Abstract] [Full Text] [Related]

  • 37. Prevalence of Mycobacterium tuberculosis resistant to bedaquiline and delamanid in China.
    He W, Liu C, Liu D, Ma A, Song Y, He P, Bao J, Li Y, Zhao B, Fan J, Cheng Q, Zhao Y.
    J Glob Antimicrob Resist; 2021 Sep 07; 26():241-248. PubMed ID: 34214699
    [Abstract] [Full Text] [Related]

  • 38. Provisional CDC guidelines for the use and safety monitoring of bedaquiline fumarate (Sirturo) for the treatment of multidrug-resistant tuberculosis.
    Centers for Disease Control and Prevention.
    MMWR Recomm Rep; 2013 Oct 25; 62(RR-09):1-12. PubMed ID: 24157696
    [Abstract] [Full Text] [Related]

  • 39. Cost-effectiveness of bedaquiline in MDR and XDR tuberculosis in Italy.
    Codecasa LR, Toumi M, D'Ausilio A, Aiello A, Damele F, Termini R, Uglietti A, Hettle R, Graziano G, De Lorenzo S.
    J Mark Access Health Policy; 2017 Oct 25; 5(1):1283105. PubMed ID: 28265350
    [Abstract] [Full Text] [Related]

  • 40. Safety and Effectiveness of 3 Novel All-Oral Shortened Regimens for Rifampicin- or Multidrug-Resistant Tuberculosis in Kazakhstan.
    Rashitov M, Franke MF, Trevisi L, Bekbolatova G, Shalimova J, Eshmetov G, Bektasov S, LaHood A, Arlyapova N, Osso E, Yedilbayev A, Korotych O, Ciobanu A, Skrahina A, Mitnick CD, Seung KJ, Algozhin Y, Rich ML.
    Clin Infect Dis; 2024 Oct 15; 79(4):1046-1053. PubMed ID: 38833593
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 79.